NBIX Dec 2024 160.000 call
| Previous close | 6.20 |
| Open | 6.20 |
| Bid | 7.70 |
| Ask | 10.90 |
| Strike | 160.00 |
| Expiry date | 2024-12-20 |
| Day's range | 6.20 - 6.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 190 |
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented a
Investor's Business DailyHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
- PR Newswire
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH.
